Home › Oncolytics Biotech Receives Buy Rating from Paradigm Capital
 

Keywords :   


Oncolytics Biotech Receives Buy Rating from Paradigm Capital

2014-09-17 19:36:48| Biotech - Topix.net

's stock had its "buy" rating reissued by investment analysts at Paradigm Capital in a note issued to investors on Wednesday. They currently have a C$8.00 price objective on the stock, down from their previous price objective of C$10.00.

Tags: buy rating capital receives

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
23.11PlayStationVitaPCH-2000
23.11GB
23.11 Malbon
23.11PING PEARL GATES
23.11WATCH
23.11L
23.11Tetsuya_SP2 DMC
23.116
More »